Cargando…

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma

Programmed cell death 1 (PD-1) checkpoint inhibitor therapy leads to immune-related adverse events (irAEs). We sought to evaluate whether the development of irAEs correlates with the treatment response in Chinese patients with advanced melanoma. In this study, we conducted a retrospective study of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jing-Jing, Wen, Xi-Zhi, Ding, Ya, Li, Dan-Dan, Zhu, Bao-Yan, Li, Jing-Jing, Weng, De-Sheng, Zhang, Xing, Zhang, Xiao-Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346077/ https://www.ncbi.nlm.nih.gov/pubmed/32516130 http://dx.doi.org/10.18632/aging.103285

Ejemplares similares

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
por: Liu, Xing, et al.
Publicado: (2021)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Down Regulation of c-FLIP(L) Enhance PD-1 Blockade Efficacy in B16 Melanoma
por: Wang, Yao, et al.
Publicado: (2019)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors
por: Zhang, You-Cheng, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
por: Ma, Yan, et al.
Publicado: (2022)

Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
por: Zhao, Lijun, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review
por: Mearns, Elizabeth S, et al.
Publicado: (2018)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
por: Villa-Crespo, Lorena, et al.
Publicado: (2022)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2021)

Analysis of Factors Influencing Safety Attitudes of Operating Room Nurses and Their Cognition and Attitudes toward Adverse Event Reporting
por: Liao, Xin, et al.
Publicado: (2022)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
por: Pourhassan, Hoda Z., et al.
Publicado: (2019)

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
por: Zhao, Honghui, et al.
Publicado: (2022)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
por: Zhang, Lin, et al.
Publicado: (2023)

Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses
por: Li, Jing, et al.
Publicado: (2019)

Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
por: Zhao, Lingdi, et al.
Publicado: (2019)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

Association between PD‐1 inhibitor‐related adverse events and frailty assessed by frailty index in lung cancer patients
por: Li, Jun, et al.
Publicado: (2023)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
por: Zhang, Yanfang, et al.
Publicado: (2023)

Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events
por: Zhang, Ruixing, et al.
Publicado: (2023)

Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
por: Weinstein, Alyona, et al.
Publicado: (2017)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b8s0b4u8hpoc9q2otdjt3qba52